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Table. The test for interaction was significant showing stronger effects of
losartan among patients with prior aspirin for both the primary endpoint
(cardiovascular mortality, fatal or non-fatal myocardial infarction, and
fatal or non-fatal stroke) (p0.016 for interaction) and myocardial in-
farction (p0.037 for interaction). 4. In hypertensive patients using the
angiotensin-ll type 1 receptor antagonist losartan, there seemed to be a
positive interaction with significant reductions for the primary endpoint
and myocardial infarction with losartan in patients using aspirin.
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Introduction: ALLHAT is the largest antihypertensive trial ever done in
the United States. Patients were initially randomized to one of 4 treat-
ment groups: Chlorthalidone, amlodipine, lisinopril and Doxazosin. Of
the 42,418 patients randomized to the antihypertensive trial, 10,356 were
also randomized to the Lipid Lowering component (LLC). The objectives
of this study, were 1) to evaluate the impact of pravastatin treatment on
all-cause mortality in a hypertensive cohort with multiple risk factors and
2) to assess the applicability of benefits to populations that had been
excluded or under-represented in previous trials (seniors, women, minor-
ity, racial and ethnic groups, diabetics, etc.). Eligible patients for the lipid
component were those with no history of coronary heart disease (CHD)
and fasting LDL cholesterol of 120-189 mg/dl on no lipid lowering
therapy, or fasting LDL cholesterol of 100-129 and history of CHD. Of
the LLC participants 5,185 were randomized to Usual Care and 5,171 to
pravastatin 40mg daily. The study physician had the option of lowering
the dose of pravastatin if poorly tolerated. Approximately 14% of LLC
participants had a history of CHD and were equally distributed to Usual
Care or Pravastatin therapy.
Results: ALLHAT over-recruited groups of patients under-repre-
sented in previous lipid lowering trials. Thus the LLC included 49%
women, 37% black patients, 32% over the age of 70, 60% current /past
smokers and 34% diabetics. Baseline characteristics, such as body mass
index, systolic and diastolic BP, serum creatinine, fasting blood glucose, and
baseline lipids were similar between the UC and PRAV participants. Dif-
ferences that emerged among the various subgroups are shown on table
below.
In Conclusion: Baseline characteristics were similar among ALLHAT
Participants randomized to UC or PRAV. Subgroups of patients under-
represented in previous trials showed substantial differences in their
baseline lipid profiles.
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Purpose: The VALUE Trial compares cardiovascular outcomes in
15,314 eligible patients from 31 countries randomized to valsartan or
amlodipine-based treatment.
Methods: The blood pressure (BP) trends are analyzed in 13,449
patients with baseline and 24 months data, and in 12,570 patients with
baseline and 30 months data.
Results: Ninety two % received antihypertensive therapy prior to
enrollment. The (entry) BP in treated patients was 153.5/ 86.9 mmHg
compared to 168.1.8/95.3 mmHg in untreated patients. After sixth
months both groups had indistinguishable BP values. At 12 months the
BP fell to 141.2/ 82.9 mmHg, at 24 month to 139.1/79.8 mmHg (p
0.0001 vs 12 months), and to 138.1/79.0 mmHg at 30 months (p
0.0001 vs 24 months). Compared to baseline (21.7%) the systolic control
BP (140 mmHg) increased to 59.5% at 24 months and 62.2% at 30
months. Similarly, the diastolic control BP (90 mmHg) increased from
53.7% at baseline to 88.6% at 24 months and 90.0% at 30 months, and
combined control (140 and 90 mmHg) increased from 18.9% at
baseline to 57.6% at 24 months and 60.5% at 30 months. All proportions
at 24 and 30 months vs baseline for diastolic, systolic and combined
control BP are highly significant (p0.0001). At 24 months 87.7% of all
patients received randomized therapy: monotherapy  39.7%, added
hydrochlorothiazide 46.0%, additional drugs permitted by the proto-
col 15.9%.
Conclusion: The VALUE Trial is executed in regular clinical settings.
The achieved BP control in this study is better than in any published
large-scale trial. Our results demonstrate that when explicit BP goal is set
and a treatment algorithm is provided, the physicians achieve much better
control rates than in their regular practice.
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Event Aspirin Pts w/events Pts w/events (%)
Angina pectoris No 93 (2.6) 107 (3.0)
Yes 48 (5.0) 53 (5.3)
Cong. heart failure No 108 (3.0) 108 (3.0)
Yes 53 (5.5) 45 (4.5)
Cardiovascular death No 158 (4.4) 148 (4.1)
Yes 76 (7.9) 56 (5.6)
Myocardial infarction
(definite)
No 130 (3.6) 154 (4.3)
Yes 58 (6.0) 44 (4.4)
Mortality No 310 (8.6) 277 (7.7)
Yes 121 (12.5) 106 (10.6)
Primary endpoint No 408 (11.3) 380 (10.6)
Yes 180 (18.6) 128 (12.7)
Stroke No 215 (5.9) 171 (4.7)
Yes 94 (9.7) 61 (6.1)
Lipid Profiles of Various Patient Sub-groups
Men Women White African Am Diabetic Non-Diabetic
Total-C 217 232* 224 226* 225 224
HDL-C 43 52* 44 52* 46 48*
LDL-C 144 149* 145 148* 146 146
Triglycerides 150 152 169 124* 158 147*
* P  .01 compared to respective subgroup
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